PQ6: Therapeutic approaches for autonomic and neuroendocrine dysfunction in cancer cachexia

Information

  • Research Project
  • 10303658
  • ApplicationId
    10303658
  • Core Project Number
    R01CA264133
  • Full Project Number
    1R01CA264133-01
  • Serial Number
    264133
  • FOA Number
    RFA-CA-20-004
  • Sub Project Id
  • Project Start Date
    9/10/2021 - 2 years ago
  • Project End Date
    8/31/2026 - 2 years from now
  • Program Officer Name
    WATSON, JOANNA M
  • Budget Start Date
    9/10/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/17/2021 - 2 years ago

PQ6: Therapeutic approaches for autonomic and neuroendocrine dysfunction in cancer cachexia

Project Summary: Illness behaviors, metabolic disturbances, and cardiovascular compromise are common in patients with chronic systemic diseases, and contribute substantially to quality of life and ultimate survival. Other illness- induced morbidities including anorexia and lethargy also compromise the ability of patients to recover from life- saving or extending interventions, and diminish the motivational drive to aggressively battle the underlying condition. Although cachexia in cancer patients was described more than two thousand years ago, the central mechanisms underlying this disorder are poorly understood. Furthermore, there is currently no effective pharmaceutical treatment. Cardiovascular impairment is common in all chronic diseases, and can be a presenting complaint in cancer patients, even prior to initiation of therapy. Our laboratory is dedicated to unraveling the basic mechanisms whereby cancer triggers neuroinflammation and subsequent chronic activation of systemic stress responses in patients with cancer. In this proposal, we will focus on understanding the scope and mechanism by which systemic illness induces chronic activation and alteration in the sympathetic nervous system. The significance of this proposal resides in its unique combination of our historical focus on neuroendocrinology and neuroinflammation, with new collaborations and efforts directed at understanding the extent and mechanisms of cardiovascular impairment and sympathetic nervous system plasticity in patients with cancer. The long-term goal of our research is to gain mechanistic understanding of the acute illness response and how it is transitioned into chronic neuroinflammation in all cancer types, in order to develop more effective therapeutic interventions.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
    281022
  • Indirect Cost Amount
    151752
  • Total Cost
    432774
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NCI:432774\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OREGON HEALTH & SCIENCE UNIVERSITY
  • Organization Department
    PEDIATRICS
  • Organization DUNS
    096997515
  • Organization City
    PORTLAND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    972393098
  • Organization District
    UNITED STATES